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Randomized controlled trial of interferon gamma versus
amantadine in combination with interferon alpha and ribavirin for
hepatitis C genotype 3 non-responders and relapsers
Zaigham Abbas, Sajjad Raza, Saeed Hamid, Wasim Jafri
Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan.
Abstract
Objectives: To evaluate the efficacy and safety of triple combination regimens comprising of interferon alpha-2b
(IFN-alpha) and ribavirin plus either IFN-gamma or amantadine in genotype 3 patients, responders or relapsers
to interferon plus ribavirin combination.
Methods: Patients were randomized to receive IFN-alpha 3MU thrice a week, ribavirin 800-1200 mg per day with
either IFN-gamma 2 MU thrice a week or amantadine 100 mg twice daily. Treatment was continued for 48 weeks
in patients showing complete or partial (2 log reduction) early virological response (EVR) at 12 weeks and
negative PCR at 24 weeks. 
Results: Total enrollments were 44; 25 were previously non-responders out of them 12 were in the IFN-gamma
arm. Nineteen were relapsers, out of them 10 received IFN-Gamma. Overall EVR with triple regimens was 61.4%
(27/44). The EVR for IFN-gamma arm was 72.7% (16/22) and for amantadine arm 50% (11/22) (p=0.089).
Sustained virological response (SVR) was 50% (11/22) in the gamma arm and 27.3% (6/22) in the amantadine
arm (p=0.122). This figure was 60% (6/10) and 44% (5/9) for relapsers (p=0.845), and 41.6% (5/12) and 7.7%
(1/13) for non-responders (p=0.046).Treatment was well tolerated by most of the patients in both arms. 
Conclusions: About one third of patients responded to the triple regimens. However IFN-gamma was a better
option. Its combination with pegylated interferon and ribavirin needs further evaluation. (Trial Registration:
ClinicalTrials.gov Identifier NCT00538811).
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Introduction
The current standard treatment for chronic hepatitis C
virus (HCV) infection is combination of pegylated interferon
(PEG-IFN) and ribavirin. The treatment is given for a period
of six months for genotype 2 and 3 and one year for genotype
1 and 4.1 This combination gives a sustained virological
response (SVR) of 54%-56%; 42-52% of patients with
genotype 1 and 76-84% of those with genotypes 2 and 3.2
Comparing PEG-IFN with standard interferon, there is much
better response by using PEG-IFN for the treatment of
genotype 1. For genotype 3, the response rate with standard
interferon and ribavirin is equally good, cost effective3,4 and
recommended by the different societies.5,6
Current standard therapy for chronic hepatitis C with
interferon alpha (standard or pegylated) and ribavirin is still
less than ideal and the problem of the non-responding patients
to the combination therapy remains.SVR remains a difficult
goal to achieve in many patients. After a relapse from
standard interferon plus ribavirin therapy, retreatment with
PEG-IFN plus ribavirin for one year may increases the
response rate to 40-50%. However, patients who have failed
to respond to combination of standard interferon and
ribavirin, re-treatment with PEG-IFN plus ribavirin therapy
has a response rate of only 10%.2 Different strategy is,
therefore, needed for patients who are considered as non-
responders to interferon and ribavirin therapy. Due to the
limitations of antiviral drugs, there is a need to explore other
avenues to enhance the immune system's ability to fight HCV.
In the context of discovery of IL-28 B gene
polymorphism coding for lambda interferon and its
importance as an independent predictor of response to
interferon alpha based therapy,7,8 there is a resurgence of
interest and enthusiasm about the role of interferon lambda
and gamma in clearing the virus. Interferon gamma (IFN-
gamma) inhibits HCV virion production by an effect on viral
RNA and protein synthesis, enhancement of immune lysis of
HCV infected cells, and inhibition of hepatic fibrosis by an
effect on TGF-beta.9 IFN- alpha and IFN-gamma induce
distinct patterns of gene expression10 and differential actions
of IFN-alpha and IFN-gamma has its implications in the
context of therapeutic intervention. 
Considering the antiviral effects of IFN-gamma and
expected favourable effects if used in combination with IFN-
alpha, we started an investigator driven study to evaluate the
efficacy of a regimen combing IFN-gamma with IFN-alpha
plus ribavirin in patients who had not responded to the
combination of last two drugs.
Patients and Methods
Trialdesign: This was a single centred investigator
initiated, open label, parallel randomized controlled trial. The
patients were divided into two arms namely experimental
(IFN-gamma) and active comparator (amantadine).
Randomization was done by opaque sealed envelope method.
Non-responders and relapsers to previous treatment with
standard interferon and ribavirin were separately
randomized.Primary end point was the efficacy in terms of
sustained virological response (SVR) defined as undetectable
HCV RNA 24 weeks after treatment discontinuation (week
72). Secondary end points were normalization of ALT at
week 72, and tolerance and safety. No changes were made in
methods after the trial commencement.
Participants: The study was conducted between July
2008 and December 2010. The patients for this were recruited
at the Aga KhanUniversityHospital, Karachi, Pakistan. The
target patients were adult males and females patients infected
with HCV genotype 3, ranging in age from 18-70 years, who
had previously received standard interferon alpha 2a of 2b
3MU thrice a week in combination with ribavirin (800-1200
mg) for 24 weeks and had not shown a response as depicted
by disappearance of HCV RNA from serum done in the last
month of therapy (non-responders) or who relapsed at six
months post-treatment (relapsers). 
Other inclusion criteria were Hb > 10 g/dL (females)
and > 11 g/dL (males), Platelets count > 100 x 109/L,
neutrophil count > 1.5 x 109/L, at least one abnormal ALT
values in the last year, normal TSH, non-pregnant adult
females and absence of drug or alcohol abuse. Exclusion
criteria were antiviral treatment in the last three months,
hepatitis B or HIV co-infection, severe renal dysfunction or
creatinine clearance less than 50 ml/min, pregnant or breast
feeding women, suspected hypersensitivity to Interferon
alpha, gamma or ribavirin, decompensated liver cirrhosis,
history or any evidence of other concomitant causes of
chronic liver disease, active malignant disease, any known
pre-existing medical condition that could interfere with
subject's participation or completion of study.
Interventions: Experimental arm received IFN-
alpha 2b 3 MU thrice a week, ribavirin 800-1200 mg per day,
and IFN-gamma 200 MU thrice a week. Patients of less than
70 kg of weight received 800 mg of ribavirin, while 70 kg or
above received 1200 mg daily. Active Comparator arm
received amantadine 100 mg twice a day in place of IFN-
gamma. Duration of therapy was 48 weeks.
Baseline evaluation: The following base line
evaluation was conducted for each patient: written informed
consent , medical history, physical examination including
height and weight, serum HCV RNA (quantitative) to measure
the viral load (RT-PCR assay: Cobas Amplicor Monitor v2.0,
Roche Diagnostics). HCV genotype determined by Innolipa
kits, abdominal ultrasound, and alpha-fetoprotein levels. A
liver biopsy was done prior to therapy. Hepatic inflammation
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and fibrosis were assessed by METAVIR scoring system. For
METAVIR system, stage of fibrosis was assessed on a scale of
0-IV and activity was graded on a scale of 0-3.Once patient
became PCR negative with the above mentioned quantitative
assay, reverse transcription polymerase chain reaction assay
with a sensitivity of 100 copies per millimeters was used in the
follow up visits.
Follow-up evaluation: Patients were followed up in
the clinic at week 2 and 4 and then at monthly intervals until
the end of treatment (48 weeks). Patients were able to contact
the investigators during the course of the treatment to report
any adverse events or side effects and for their queries if
any.Following evaluation was performed at each visit. a.
physical examination b. assessment of any adverse event. c.
Concurrent medication d. Verbal check of compliance e. CBC
and biochemistry. Determination of serum HCV RNA was
performed at 0, 12, 24 and 48 weeks, and then12 and 24
weeks post treatment (72 weeks). PCR at baseline and 12
weeks was quantitative.
Outcomes: Patients were evaluated for response to
therapy which was defined as clearance or 2 log reduction of
HCV RNA levels at 12 weeks (early virological response or
EVR) and negativity of serum HCV RNA by PCR at 24
weeks. Patients who were considered as responders continued
the study till the end of treatment (48 weeks). Non-responders
at 24 weeks were withdrawn from the study. Patients who
successfully completed 48 weeks of the study were seen at 12
weeks and 24 weeks after treatment discontinuation and were
evaluated for the sustained response.No changes to trial
outcomes were made after the trial commencement.
Randomization: Simple randomization was done
using sealed envelope method. Non-responders and relapsers
to previous treatment with standard interferon and ribavirin
were separately randomized. Randomization, enrollment of
participants and assignment of participants to interventions was
done by the principal investigator. It was an open label study.
Safety and ethical issues: Treatment was aimed to be
interrupted if subject's health or wellbeing was considered
threatened by continuation of the treatment, occurrence of
serious adverse events or any unmanageable factors, and
withdrawal of consent by the subject. Adverse events were
graded as mild, moderate, severe and life threatening. Therapy
was permanently discontinued for life-threatening events.
Doses of both interferons were reduced to half if the
neutrophil count fell between 0.75 and 0.5 x 106/L and/or
platelets fell below 60 x 106/L. If neutrophil count fell below
0.5 x 106/L or platelets below 30 x 109/L therapy was stopped.
Ribavirin dose was lowered to half if haemoglobin levels fell
below 8.5 g/dl and stopped if level fell below 7.5 g/dl.
Ethical Review Committee of the Institute approved
the study. Written informed consent was obtained from all the
patients before enrolling the patients in the study after
explaining the study objectives and methodology.
Statistical methods: Data was analyzed by the
Statistical Package for Social Sciences SPSS 16.0 for
Windows (SPSS inc. Chicago, IL). Means with standard
deviations were calculated for continuous variables, and
compared through Wilcoxon rank-sum test Proportions were
calculated for categorical variables, and compared using the
Chi square test with Yate's correction. The statistical
significance level of two-sided tests was set at P=0.05.
Results
Participant flow: The total number of patients
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Table-1: Baseline characteristics of study patients.
Gamma interferon arm (n=22) Amantadine arm (n=22) P value
Age (years) 44.95±10.1 42.32 ±8.5 0.451
Male sex 15 (68.2%) 13 (59.1%) 0.754
Body mass index, kg/m2 28.57 ±6.3 25.72 ±3.9 0.163
Haemoglobin, g/dL 14.0 ±1.76 13.06 ±2.0 0.144
Total leukocyte count (109/L) 6.84 ±1.59 6.44 ±1.81 0.386
Platelet count (109/L) 232.6±89.8 193. 2±97.5 0.156
Bilirubin (mg/dl) 0.70 ±0.36 0.88 ±0.54 0.275
Alanine aminotransferase (IU/L) 88.82 ±65.4 70.10 ±41.9 0.406
Gamma glutamyltransferase (IU/L) 51.29 ±31.9 59.00 ±42.23 0.723
Alkaline phosphatase (IU/L) 112.14 ±58.7 103.05 ±55.6 0.715
Fasting blood sugar (mg/dL) 100.00 ±32.9 98.33 ±7.5 0.309
HCV RNA titer (IU/mL) 606691.2 ±872128.9 947214.6 ±1266694.8 0.346
Liver biopsy Grade
0-1 5 8 0.509
3-Feb 17 14
Liver biopsy stage
0-2 15 5 1
4-Mar 7 7
Values are means ± standard deviation or n(%).
included in this study were 44 out of which 28 (63.6%) were
male and 16 (36.4%) female; mean age 43.6± 9.3years
(range 28-60). Twenty two were in the experimental arm
and 22 in the active comparator group, Out of the 44
patients,25 were previously non-responders and 12 of them
were in the IFN-gamma arm. Nineteen were relapsers; 10
received IFN-gamma.
Baseline data: Out of the total recruited patients 9
(22.3%) were diabetic, 8 (20 %) hypertensive, 12 (31.6%)
had hepatomegaly and 8 (20.5%) had splenomegaly. Liver
biopsy revealed no fatty change in 16 (57.1%), mild fatty
change in 8 (28.6%), moderate fatty change in 4 (14.3%)
patients. F3 or F4 fibrosis was seen in 14 (34%). Baseline
characteristics are summarized in the Table-1.
Virological response: By intention-to-treat analysis,
the overall early virological response (EVR) with triple
regimens was 61.4% (27/44). The EVR for IFN-gamma arm
was 72.7% (16/22) and for amantadine arm 50% (11/22) (p =
0.089). In the subgroup analysis, this figure was 90% (9/10)
and 55% (5/9) for relapsers (p=0.119), and 46.1% (7/12) and
8% (6/13) for non-responders in both arms respectively
(p=0.543). 
The overall end of treatment response (ETR) was
40.9% (18/44). The ETR was 50% (11/22) and 31.8% (7/22)
for IFN-gamma and amantadine arms respectively (p=
0.220). In the subgroup analysis, this figure was 60% (6/10)
and 55% (5/9) for relapsers (p=0.845), and 41.6% (5/12) and
15.3% (2/13) for non-responders to previous treatments in
both arms respectively (p=0.144). 
Sustained virological response (SVR) with both triple
regimens was seen in 38.6% (17/44). SVR was 50% (11/22)
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Table-2: Comparison between patients who achieved sustained virological response (SVR) with those who did not achieve SVR.
Patients with SVR Patients without SVR P value
Baseline Characteristics
Mean age (years) 42.81 ±9.7 44.07 ±9.2 0.715
Male sex n(%) 13 (76.5%) 15 (55.6%) 0.279
Body mass index 26.85 ±4.4 27.28 ±5.7 0.754
Haemoglobin (g/dl) 13.90 ±1.9 13.32 ±1.8 0.481
Total leukocyte count (109/L) 6.82 ±1.5 6.52 ±1.8 0.552
Platelet count (109/L) 222.2±125.9 206.3±71.3 0.885
Bilirubin (mg/dl) 0.84 ±0.4 0.75 ±0.5 0.23
Mean ALT (U/L) 77.35 ±58.9 81.64 ±54.5 0.682
Gamma GT (U/L) 47.20 ±23.9 59.79 ±42.7 0.567
ALP ( U/L) 105.00 ±48.8 109.44 ±62.1 > 0.999
Fasting blood sugar (mg/dl) 110.75 ±35.5 94.00 ±24.6 0.174
Diabetic 2 7 0.494
Mean HCV RNA titer (IU/mL) 958279.6 ±1409331.2 673982.8 ±862324.1 0.594
Baseline PCR <500000 12 17 0.847
Liver biopsy Grade: 0-1 5 8 > 0.999
2-3 12 19
Liver biopsy stage: 0-II 11 19 0.952
III-IV 6 8
Responses
Early Virological Response 17 10 < 0.0001*
Early biochemical response 15 22 0.863
End of treatment virological response 17 1 < 0.0001*
End of treatment biochemical response 16 2 0.0001*
Received IFN-Gamma 11 11 0.216
“Non-responders” who Received IFN-gamma 5 7 0.046*
“Relapsers” who Received IFN-gamma 6 4 0.669
Values are in numbers or means ± standard deviation. *Significant p values.
Figure: Response to the therapy. Terms "non responders" and "relapsers" refer to the
subgroups based on response to previous therapies.
in IFN-gamma arm and 27.27% (6/22) in amantadine arm
(p=0.122). In the subgroup analysis, this figure was 60%
(6/10) and 44% (5/9) for relapsers (p=0.845), and 41.6%
(5/12) and 7.69% (1/13) for non-responders in both arms
respectively (p=0.046). 
Biochemical response: The normalization of ALT
at week 12 was seen in 84.1% (37/44) patients. It was
86.3% (19/22) and 81.1% (18/22) for IFN-gamma and
amantadine arms respectively (p= 0.680). In the subgroup
analysis, this figure was 100% (10/10) and 77.7% (7/9) for
relapsers (p=0.115), and 75% (9/12) and 84.6% (11/13) for
non-responders to previous treatments in both arms
respectively (p=0.548).
Normalization of ALT at the end of treatment was
seen in 41% (18/44) patients. It was 50% (11/22) and 31.8%
(7/22) for IFN-gamma and amantadine arms respectively (p=
0.220). In the subgroup analysis, this figure was 70% (7/10)
and 55% (5/9) for relapsers (p=0.515), and 33.3% (4/12) and
15.3% (2/13) for non-responders to previous treatments in
both arms respectively (p=0.294).
The sustained normalization of ALT at six months
post treatment was seen in 38.6% (17/44) patients. It was
50% (11/22) and 27.3% (6/22) for IFN-gamma and
amantadine arms respectively (p= 0.122). In the subgroup
analysis, this figure was 60% (6/10) and 55% (5/9) for
relapsers (p=0.845), and 41.6% (5/12) and 7.6% (1/13) for
non-responders to previous treatments in both arms
respectively (p=0.047).
Assessment of adverse events: Treatment was well
tolerated in both arms.The 80/80/80 rule i.e. 80% of the drug
taken for 80% of the scheduled time was well followed. Mild
adverse events included fever, headache, body ache, joint
pain, weakness, disturbed sleep, retrosternal burning,
decreased appetite, hairloss, weight loss, abdominal
discomfort, nausea, vomiting, burning sensation in hands and
feet, disturbed sleep and bloating. Treatment was stopped in
two patients due to severe adverse events including severe
neutropenia in one patient and arthralgia involving knee joint
in the other. Both these patients belonged to the active
comparator (amantadine) group. Dose reduction was done in
one patient in gamma arm because of complaints of hand
tremors and jerky movements.
Discussion
This is the first study to examine IFN-gamma in
combination with IFN-alpha and ribavirin for difficult to treat
hepatitis C patients. Previously, in a small pilot study of IFN-
gamma monotherapy given for four weeks, in the doses of
100-400 microgram thrice weekly, the drug was well
tolerated. It did not show any effect on the serum HCV RNA
levels.11However, another study of monotherapy given for 24
weeks showed improvement in liver fibrosis.12 There was
successful eradication of virus with a combination of IFN-
gamma, interferon alfacon-1, and ribavirin in a nonresponder
HCV patient to pegylated interferon therapy.13
Combining IFN-gamma with IFN-alpha appears
logical. When administered simultaneously, IFN-alpha
together with IFN-gamma results in dramatic enhancement of
antiviral activity against hepatitis C.14 There is a distinct
pattern of gene expression by two interferons.10 The
synergistic effect is likely to be due to differential cell surface
receptors and signaling pathways employed.15 IFN-gamma
enhances the production of IFN-alpha from immature
plasmocytoid dendritic cells.16 Moreover, IFN-alpha can
inhibit production of IL-12, a potent activator of STAT4 and
IFN-gamma production17 which again stresses the importance
of IFN-gamma supplementation in anti-HCV regimens. 
Direct anti-HCV effect of IFN-gamma in cell culture
is, at least in part, mediated through the Ras-MAPK signaling
pathway, which possibly involves a direct or indirect
modulation of NS5A protein phosphorylation.18 The
mechanism of action of IFN-gamma in inhibiting the HCV
infection may involve the down regulation of Claudin-1
expression and HCV receptors' distribution.19 Ribavirin has
shown to enhance IFN-gamma levels in patients with chronic
hepatitis C treated with interferon-alpha.20 So immune
responses may further be enhanced with better efficacy by
combining IFN-gamma with IFN-alpha plus ribavirin for
treatment of chronic hepatitis C. IFN-gamma has potent anti-
fibrotic effects on stellate cells. Even if the combination does
not clear HCV, it would slow or prevent fibrosis.12,21
In our study we used standard interferon instead of
pegylated interferon for the retreatment. In our country the
cost of pegylated interferon based therapy is exorbitant and
out of the reach of an ordinary person. Moreover, pegylated
interferon with ribavirin is not an effective choice for
retreatment of failures of standard interferon plus ribavirin
therapy.2 In the comparator group, we used amantadine. Role
of amantadine in combination with interferion and ribavirin
for the treatment of hepatitis C remains controversial.
Previous studies related to retreatment of difficult to treat
patients have shown contradictory results; some studies
favour22,23 while others refute its role.24,25 We considered it
unethical to retreat patients with dual combination of
standard interferon with ribavirin again and compare it with
a triple regimen.
The strength of this study is that first time IFN-
gamma was used in combination with IFN-alpha plus
ribavirin to treat difficult to treat hepatitis C patients. The
combination was found to be safe and effective especially in
non-responders to previous treatment. There are certain
weaknesses in this trial which include using standard
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interferon instead pegylated interferon, small sample size of
the study and including genotype 3 only. This was an
investigator initiated trial, with limited financial support. As
IFN-gamma is not registered in our country, we were granted
special permission by the Ministry of Health to import this
drug once for this study. We did not include genotype 1, as
preferred interferon for this genotype even for naïve patients
is pegylated interferon. We included in this study all the
patients regardless of degree of fibrosis as the goals of
therapy are to prevent complications and death from HCV
infection; regardless of the stage of fibrosis.26 Moreover
patients with advanced fibrosis need prompt intervention.27,28
Conclusion
In conclusion, this single centre randomized study
indicates that half of the patients with HCV genotype 3
infection who were retreated with a combination of IFN-
gamma with interferon alpha plus ribavirin achieved a
sustained virological response. This response rate was better
than comparator triple regimen which included amantadine.
Whether our strategy of including IFN-gamma for retreatment
is indeed effective, needs further evaluation by combining it
with pegylated interferon plus ribavirin in a bigger study
recruiting all genotypes. It may be worthwhile evaluating IFN-
gamma in combination with the standard of care for patients
who had unfavourable IL-28 B genotype polymorphisms
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